Literature DB >> 21972211

The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia.

Andreia Maria Camargos Rocha1, Cláudia Souza, Gifone Aguiar Rocha, Fabrício Freire de Melo, Nelma Cristina Diogo Clementino, Marília Campos Abreu Marino, Adriana Bozzi, Maria Luiza Silva, Olindo Assis Martins Filho, Dulciene Maria Magalhães Queiroz.   

Abstract

Th17 cells have been associated with immune-mediated diseases in humans but it has still not been determined whether they play a role in immune thrombocytopenia. We evaluated representative cytokines of the Th17, Th1, Th2 and Treg cell commitment in the serum of patients with chronic immune thrombocytopenia, as well as the cell source of IL-17A. Higher levels of IL-17A and Th17-related cytokines, and an increased percentage of IL-17A producing CD4+ and neutrophils were observed in patients. The levels of cytokines involved in Th1 cell commitment IFN-γ, IL-2, IL12-p70 and the percentages of Th1 cells were also increased, but IL-4 was not detected. Although the concentrations of IL-10 were higher, the levels of TGF-β were similar in both groups. In conclusion, our results point to a putative role for Th-17 cells/IL-17A cytokine in the pathogenesis of chronic immune thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21972211      PMCID: PMC3186321          DOI: 10.3324/haematol.2011.046417

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura.

Authors:  Jingbo Zhang; Daoxin Ma; Xiaojuan Zhu; Xun Qu; Chunyan Ji; Ming Hou
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 2.  Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production.

Authors:  Robert McMillan
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

3.  IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia.

Authors:  Andreia Maria Camargos Rocha; Cláudia De Souza; Gifone Aguiar Rocha; Fabrício Freire De Melo; Isadora Sofia Borges Saraiva; Nelma Cristina Diogo Clementino; Marília Campos Abreu Marino; Dulciene Maria Magalhães Queiroz
Journal:  Br J Haematol       Date:  2010-09       Impact factor: 6.998

4.  Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia.

Authors:  Xiaojuan Zhu; Daoxin Ma; Jingbo Zhang; Jun Peng; Xun Qu; Chunyan Ji; Ming Hou
Journal:  J Clin Immunol       Date:  2009-12-10       Impact factor: 8.317

5.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

6.  Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response.

Authors:  Fotios P Panitsas; Maria Theodoropoulou; Alexandra Kouraklis; Marina Karakantza; Georgios L Theodorou; Nicholas C Zoumbos; Alice Maniatis; Athanasia Mouzaki
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

Review 7.  International consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

8.  Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept.

Authors:  J R McMinn; Stephen Cohen; Joseph Moore; Scott Lilly; Joan Parkhurst; Michael D Tarantino; Deirdra R Terrell; James N George
Journal:  Am J Hematol       Date:  2003-06       Impact factor: 10.047

9.  Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Authors:  Agnès Doreau; Alexandre Belot; Jérémy Bastid; Benjamin Riche; Marie-Claude Trescol-Biemont; Bruno Ranchin; Nicole Fabien; Pierre Cochat; Claire Pouteil-Noble; Pierre Trolliet; Isabelle Durieu; Jacques Tebib; Berhouz Kassai; Stéphane Ansieau; Alain Puisieux; Jean-François Eliaou; Nathalie Bonnefoy-Bérard
Journal:  Nat Immunol       Date:  2009-05-31       Impact factor: 25.606

10.  Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity.

Authors:  J W Semple; Y Milev; D Cosgrave; M Mody; A Hornstein; V Blanchette; J Freedman
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

View more
  30 in total

Review 1.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

Review 2.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.

Authors:  Guanfang Shi; David J Field; Kyung-ae Ko; Sara Ture; Kalyan Srivastava; Scott Levy; M Anna Kowalska; Mortimer Poncz; Deborah J Fowell; Craig N Morrell
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

4.  Time-Restricted Feeding Alters the Innate Immune Response to Bacterial Endotoxin.

Authors:  Yasmine M Cissé; Jeremy C Borniger; Elise Lemanski; William H Walker; Randy J Nelson
Journal:  J Immunol       Date:  2017-12-04       Impact factor: 5.422

5.  Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia.

Authors:  YiChan Zhang; TingTing Ma; Xuan Zhou; JunHao Chen; Juan Li
Journal:  Int J Hematol       Date:  2018-01-11       Impact factor: 2.490

6.  Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients.

Authors:  Feng Li; Lili Ji; Weiguang Wang; Fanli Hua; Yanxia Zhan; Shanhua Zou; Ling Yuan; Yang Ke; Zhihui Min; Dongli Song; Lihua Sun; Hao Chen; Yunfeng Cheng
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

7.  Differential regulation of interleukin-12 (IL-12)/IL-23 by Tim-3 drives T(H)17 cell development during hepatitis C virus infection.

Authors:  Jia M Wang; Lei Shi; Cheng J Ma; Xiao J Ji; Ruo S Ying; Xiao Y Wu; Ke S Wang; Guangyu Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

9.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

10.  CD16+ monocytes control T-cell subset development in immune thrombocytopenia.

Authors:  Hui Zhong; Weili Bao; Xiaojuan Li; Allison Miller; Caroline Seery; Naznin Haq; James Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.